DK0941095T3 - Forbedrede farmaceutiske sammensætninger - Google Patents

Forbedrede farmaceutiske sammensætninger

Info

Publication number
DK0941095T3
DK0941095T3 DK97948461T DK97948461T DK0941095T3 DK 0941095 T3 DK0941095 T3 DK 0941095T3 DK 97948461 T DK97948461 T DK 97948461T DK 97948461 T DK97948461 T DK 97948461T DK 0941095 T3 DK0941095 T3 DK 0941095T3
Authority
DK
Denmark
Prior art keywords
improved
pharmaceutical compositions
improved pharmaceutical
resuspendability
suspensions
Prior art date
Application number
DK97948461T
Other languages
Danish (da)
English (en)
Inventor
Todd P Foster
David L Kiefer
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25194373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0941095(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DK0941095T3 publication Critical patent/DK0941095T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97948461T 1996-12-09 1997-12-03 Forbedrede farmaceutiske sammensætninger DK0941095T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/806,584 US5736151A (en) 1996-12-09 1996-12-09 Antibiotic oil suspensions
PCT/US1997/021401 WO1998025621A1 (en) 1996-12-09 1997-12-03 Improved pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK0941095T3 true DK0941095T3 (da) 2004-08-02

Family

ID=25194373

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97948461T DK0941095T3 (da) 1996-12-09 1997-12-03 Forbedrede farmaceutiske sammensætninger

Country Status (21)

Country Link
US (1) US5736151A (cg-RX-API-DMAC7.html)
EP (1) EP0941095B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001505910A (cg-RX-API-DMAC7.html)
KR (1) KR100544248B1 (cg-RX-API-DMAC7.html)
CN (1) CN100413506C (cg-RX-API-DMAC7.html)
AT (1) ATE264681T1 (cg-RX-API-DMAC7.html)
AU (1) AU746666B2 (cg-RX-API-DMAC7.html)
BR (1) BR9714967B1 (cg-RX-API-DMAC7.html)
CA (1) CA2269682C (cg-RX-API-DMAC7.html)
CZ (1) CZ297632B6 (cg-RX-API-DMAC7.html)
DE (1) DE69728783T2 (cg-RX-API-DMAC7.html)
DK (1) DK0941095T3 (cg-RX-API-DMAC7.html)
ES (1) ES2218705T3 (cg-RX-API-DMAC7.html)
FI (1) FI991302L (cg-RX-API-DMAC7.html)
HU (1) HUP0000564A3 (cg-RX-API-DMAC7.html)
NO (1) NO325475B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ336183A (cg-RX-API-DMAC7.html)
PL (1) PL190662B1 (cg-RX-API-DMAC7.html)
PT (1) PT941095E (cg-RX-API-DMAC7.html)
SK (1) SK72399A3 (cg-RX-API-DMAC7.html)
WO (1) WO1998025621A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
AU8832301A (en) * 2000-09-12 2002-03-26 Upjohn Co Pharmaceutical composition having modified carrier
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
EP1528926A1 (en) * 2002-08-07 2005-05-11 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
ES2270361T3 (es) * 2003-03-20 2007-04-01 Pharmacia Corporation Formulacion dispersable de un agente antiinflamatorio.
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
AU2004258746A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
KR101434706B1 (ko) * 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 미립자 유성 현탁액을 포함하는 의약 조성물
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
NZ592984A (en) * 2008-11-19 2012-12-21 Merial Ltd Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
PL2874624T3 (pl) 2012-07-17 2020-07-27 Bayer New Zealand Limited 3 Argus Place Hillcrest, Auckland 0627 / NZ Wstrzykiwalne formulacje antybiotykowe i sposoby ich zastosowania
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
US10420776B2 (en) 2016-10-13 2019-09-24 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
NL260648A (cg-RX-API-DMAC7.html) * 1961-01-31
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
DE3650526T2 (de) * 1985-08-12 1996-10-31 Upjohn Co Umwandlung des cephalosporin-hydrohalid-salzes zu einem alkalimetallsalz
US5134137A (en) * 1987-11-10 1992-07-28 The Upjohn Company Cephalosporin antibiotics
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
KR920702616A (ko) * 1989-06-13 1992-10-06 원본미기재 약제를 전달하기 위한 무수 오일-기제된 액체 현탁액
ATE202109T1 (de) * 1993-03-12 2001-06-15 Upjohn Co Kristallines ceftiofur (freie säure)

Also Published As

Publication number Publication date
FI991302A0 (fi) 1999-06-08
EP0941095A1 (en) 1999-09-15
CZ297632B6 (cs) 2007-02-14
CA2269682A1 (en) 1998-06-18
ATE264681T1 (de) 2004-05-15
CZ202599A3 (cs) 1999-09-15
AU746666B2 (en) 2002-05-02
ES2218705T3 (es) 2004-11-16
EP0941095B1 (en) 2004-04-21
HK1023292A1 (zh) 2000-09-08
BR9714967A (pt) 2001-10-30
CN100413506C (zh) 2008-08-27
BR9714967B1 (pt) 2010-06-29
DE69728783T2 (de) 2005-03-31
NO992780D0 (no) 1999-06-08
NO325475B1 (no) 2008-05-13
JP2001505910A (ja) 2001-05-08
AU5452998A (en) 1998-07-03
KR20000069360A (ko) 2000-11-25
SK72399A3 (en) 2000-05-16
FI991302A7 (fi) 1999-06-08
KR100544248B1 (ko) 2006-01-23
NO992780L (no) 1999-06-08
US5736151A (en) 1998-04-07
WO1998025621A1 (en) 1998-06-18
DE69728783D1 (de) 2004-05-27
CN1238690A (zh) 1999-12-15
PT941095E (pt) 2004-08-31
HUP0000564A3 (en) 2001-01-29
CA2269682C (en) 2009-04-14
NZ336183A (en) 2000-12-22
PL190662B1 (pl) 2005-12-30
FI991302L (fi) 1999-06-08
HUP0000564A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
FI991302A0 (fi) Parannetut farmaseuttiset koostumukset
IL149163A0 (en) Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
EA199901100A1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
NZ505163A (en) Sustained release medicinal compositions comprising an ionic compound with an opposite charge to the ionic active substance
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
FR2743562B1 (fr) Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
EA200100983A1 (ru) Производные 13-метилэритромицина
PE20001297A1 (es) Antibioticos cetolidos carbamato y carbazato
EA200100774A1 (ru) Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов
TR200102030T2 (tr) Benzoheterosikliller
EA200100516A1 (ru) Производные 3,3-биарилпиперидина и 2,2-биарилморфолина
DE69626981D1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amide
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
DK0832075T3 (da) N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzo-diazepin-3-yl)-3-amider
IT1277663B1 (it) Sospensioni acquose stabili di mesalazina per uso topico
ATE236888T1 (de) N-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5- benzodiazepin-3-yl)-3-amide
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
EA200000522A1 (ru) 5-htагонисты
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их